@article{oai:niigata-u.repo.nii.ac.jp:00022527,
 author = {横森, 忠紘},
 issue = {3},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {Mar},
 note = {Since advanced breast cancer is a systemic disease, this disease frequently shows hematogenous and multiple metastasis. Therefore, advanced and/or recurrent breast cancer is mainly subjected to systemic treatment, such as endocrine therapy, chemotherapy and immunotherapy, and supplemented with local therapy according to the location of each lesion, such as local resection, arterial infusion and radiotherapy. Multiple agent therapy, employing adriamycin as a main drug, has been widely accepted as chemotherapy at the present time. Internal endocrine therapy with tamoxifen (TAM) or medroxyprogesterone acetate (MPA) has taken the leading role in endocrine therapy. We have also made an attempt to combine chemotherapy with endocrine therapy, chemoendocrine therapy, and/or to use various hormone preparations, multihormone therapy, in expectation of further reinforcement of therapeutic efficacy. Before the initiation of treatment of breast cancer, we should carefully select the most suitable treatment regimen to conditions of individual patients with consideration of the state of ER (PgR), locations and severities of metastasized lesions, previous treatment and a degree of its efficacy, presence or absence of menopause, and performance status.},
 pages = {174--178},
 title = {5) 再発・進行乳癌の治療(シンポジウム 乳癌をめぐる諸問題, 第448回新潟医学会)},
 volume = {104},
 year = {1990}
}